1. Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist. Issue 5 (23rd March 2018) Authors: Guzman, Cristina B.; Duvvuru, Suman; Akkari, Anthony; Bhatnagar, Pallav; Battioui, Chakib; Foster, Wendra; Zhang, Xiaotian Michelle; Shankar, Sudha S.; Deeg, Mark A.; Chalasani, Naga; Hardy, Thomas A.; Kazda, Christof M.; Pillai, Sreekumar G. Journal: Hepatology communications Issue: Volume 2:Issue 5(2018) Page Start: 561 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Issue 11 (8th June 2017) Authors: Guzman, Cristina B.; Zhang, Xiaotian M.; Liu, Rong; Regev, Arie; Shankar, Sudha; Garhyan, Parag; Pillai, Sreekumar G.; Kazda, Christof; Chalasani, Naga; Hardy, Thomas A. Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 11(2017) Page Start: 1521 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes. Issue 8 (27th March 2017) Authors: Kazda, Christof M.; Frias, Juan; Foga, Irene; Cui, Xuewei; Guzman, Cristina B.; Garhyan, Parag; Heilmann, Cory; Yang, Jihui Anne; Hardy, Thomas A. Journal: Diabetes, obesity & metabolism Issue: Volume 19:Issue 8(2017) Page Start: 1071 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗